Cytosorbents (NASDAQ:CTSO) CEO Phillip Chan Purchases 251,136 Shares

Cytosorbents Corporation (NASDAQ:CTSO) CEO Phillip Chan purchased 251,136 shares of Cytosorbents stock in a transaction that occurred on Friday, June 12th. The stock was purchased at an average price of $0.40 per share, with a total value of $100,454.40. Following the completion of the purchase, the chief executive officer directly owned 1,734,099 shares in the company, valued at $693,639.60. This trade represents a 16.93% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Cytosorbents Stock Up 8.1%

CTSO stock opened at $0.43 on Tuesday. Cytosorbents Corporation has a fifty-two week low of $0.37 and a fifty-two week high of $1.39. The company has a debt-to-equity ratio of 4.70, a current ratio of 1.09 and a quick ratio of 0.81. The stock has a market capitalization of $27.13 million, a price-to-earnings ratio of -2.27 and a beta of 1.35. The business’s fifty day moving average price is $0.54 and its two-hundred day moving average price is $0.63.

Cytosorbents (NASDAQ:CTSO) last announced its earnings results on Wednesday, May 13th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Cytosorbents had a negative net margin of 31.85% and a negative return on equity of 235.57%. The business had revenue of $8.86 million during the quarter, compared to the consensus estimate of $9.40 million. On average, equities analysts anticipate that Cytosorbents Corporation will post -0.19 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on CTSO shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a research report on Wednesday, April 8th. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a research note on Thursday, March 26th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $5.38.

Hedge Funds Weigh In On Cytosorbents

Several hedge funds have recently bought and sold shares of CTSO. Avenir Corp boosted its position in shares of Cytosorbents by 2.9% during the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock worth $3,343,000 after acquiring an additional 147,261 shares in the last quarter. Vanguard Group Inc. raised its position in Cytosorbents by 3.7% during the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after purchasing an additional 79,535 shares in the last quarter. CM Management LLC lifted its stake in Cytosorbents by 14.6% during the fourth quarter. CM Management LLC now owns 1,476,500 shares of the medical research company’s stock worth $944,000 after purchasing an additional 188,372 shares during the last quarter. CIBC Bancorp USA Inc. bought a new stake in Cytosorbents during the third quarter worth $161,000. Finally, Citadel Advisors LLC boosted its holdings in shares of Cytosorbents by 127.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after purchasing an additional 36,790 shares in the last quarter. 32.87% of the stock is owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.